RET/PTC rearrangement in benign and malignant thyroid diseases: A clinical standpoint

European Journal of Endocrinology

Volumn 165, Issue 4, 2011, Pages 499-507

  Marotta, Vincenzo ^a   Guerra, Anna ^b   Sapio, Maria Rosaria ^b   Vitale, Mario ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA; PROTEIN RET;

AMPLICON; ASPIRATION BIOPSY; CYTOPATHOLOGY; DIFFERENTIAL DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE REARRANGEMENT; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE RET; PATHOPHYSIOLOGY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RADIATION EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY ANALYSIS; SOUTHERN BLOTTING; THYROID CANCER; THYROID DISEASE; THYROID NODULE; THYROID PAPILLARY CARCINOMA;

BIOPSY; CARCINOMA, PAPILLARY; DNA, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS C-RET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID DISEASES; THYROID NEOPLASMS; THYROID NODULE;

EID: 80053500306     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0499     Document Type: Review

References (80)

1. Gharib H & Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Annals of Internal Medicine 1993 118 282-289. (Pubitemid 23046388)
2. Baloch ZW & LiVolsi VA. Fine-needle aspiration of thyroid nodules: past, present, and future. Endocrine Practice 2004 10 234-241.
3. Vitale M, Bassi V, Illario M, Fenzi G, Casamassima A & Rossi G. Loss of polarity and de novo expression of the beta 1 family of integrins in thyroid tumors. International Journal of Cancer 1994 59 185-190. (doi:10.1002/ijc. 2910590208)
4. V600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocrine-Related Cancer 2007 14 1089-1097. (doi:10.1677/ERC-07-0147)
5. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, De la Chapelle A & Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Modern Pathology 2005 18 48-57. (doi:10.1038/modpathol.3800235)
6. Vitale M, Bassi V, Fenzi G, Macchia PE, Salzano S & Rossi G. Integrin expression in thyroid cells from normal glands and nodular goiters. Journal of Clinical Endocrinology and Metabolism 1993 76 1575-1579. (doi:10.1210/jc.76.6. 1575)
7. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, Della Porta G & Vecchio G. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987 328 170-172. (doi:10.1038/328170a0)
8. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, Picone A, Portella G, Santelli G, Vecchio G & Fusco A. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996 12 1821-1826. (Pubitemid 26146307)
9. Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M &Fusco A. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995 11 1207-1210.
10. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N, Peix JL, Paulin C, Fabien N, Vecchio G, Jenkins RB & Fusco A. RET oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. Journal of Clinical Investigation 1992 89 1517-1522. (doi:10.1172/JCI115743)
11. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P, Di Santo A, Caruso G, Carli AF, Brilli L, Montanaro A &Pacini F. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. Journal of Clinical Endocrinology and Metabolism 2010 95 1365-1369. (doi:10.1210/jc.2009-2103)
12. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F & Santoro M. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2004 89 5175-5180. (doi:10.1210/jc.2003-032221)
13. Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, Bommarito A, Citarrella R, Lo Coco R, Cabibi D, Lo Coco A, Frasca F, Gulotta G, Latteri MA, Modica G, Galluzzo A & Giordano C. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAFV600E mutation and RET/PTC rearrangement. Thyroid 2007 17 1109-1115. (doi:10.1089/thy.2007.0008)
14. Cheung CC, Carydis B, Ezzat S, Bedard YC & Asa SL. Analysis of RET/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2001 86 2187-2190. (doi:10.1210/jc.86.5.2187)
15. V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology 2005 16 27-31. (doi:10.1111/j.1365-2303.2004.00223.x)
16. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K & Nikiforova MN. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. Journal of Clinical Endocrinology and Metabolism 2009 94 2092-2098. (doi:10.1210/jc.2009-0247)
17. Ishizaka Y, Kobayashi S, Ushijima T, Hirohashi S, Sugimura T &Nagao M. Detection of RetTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 1991 6 1667-1672. (Pubitemid 21924271)
18. Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, Basolo F, Demidchik EP, Miccoli P, Pinchera A &Pacini F. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. Journal of Clinical Endocrinology and Metabolism 2001 86 3211-3216. (doi:10.1210/jc.86.7.3211)
19. Nikiforova MN, Caudill CM, Biddinger P & Nikiforov YE. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. International Journal of Surgical Pathology 2002 10 15-22. (doi:10.1177/106689690201000104)
20. Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M & Suarez HG. High prevalence of activating RET proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997 15 1263-1273. (doi:10.1038/sj.onc.1200206)
21. Unger K, Zitzelsberger H, Salvatore G, Santoro M, Bogdanova T, Braselmann H, Kastner P, Zurnadzhy L, Tronko N, Hutzler P &Thomas G. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2004 89 4272-4279. (doi:10.1210/jc.2003-031870)
22. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M & Nikiforov YE. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. Journal of Clinical Endocrinology and Metabolism 2006 91 3603-3610. (doi:10.1210/jc.2006-1006)
23. Tallini G & Asa SL. RET oncogene activation in papillary thyroid carcinoma. Advances in Anatomic Pathology 2001 8 345-354. (doi:10.1097/00125480- 200111000-00005)
24. Guerra A, Sapio MR, Marotta V, Campanile E, Moretti MI, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G & Vitale M. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocrine Journal 2011 58 31-38. (doi:10.1507/endocrj.K10E-260)
25. Marotta V, Guerra A, Sapio MR, Campanile E, Motta M, Fenzi G, Rossi G & Vitale M. Growing thyroid nodules with benign histology and RET rearrangement. Endocrine Journal 2010 57 1081-1087. (doi:10.1507/endocrj.K10E- 229)
26. Sapio MR, Guerra A, Marotta V, Campanile E, Formisano R, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G & Vitale M. High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. Journal of Clinical Endocrinology and Metabolism 2011 96 E916-E919. (doi:10.1210/jc.2010-1599)
27. Takahashi M, Ritz J & Cooper GM. Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell 1985 42 581-588. (doi:10.1016/0092-8674(85)90115-1)
28. Durbec PL, Larsson-Blomberg LB, Schuchardt A, Costantini F &Pachnis V. Common origin and developmental dependence on c-RET of subsets of enteric and sympathetic neuroblasts. Development 1996 122 349-358. (Pubitemid 26038446)
29. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F &Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994 367 380-383. (doi:10.1038/367380a0)
30. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibanez CF & McDonald NQ. Structure and chemical inhibition of the RET tyrosine kinase domain. Journal of Biological Chemistry 2006 281 33577-33587. (doi:10.1074/jbc.M605604200)
31. Bunone G, Uggeri M, Mondellini P, Pierotti MA & Bongarzone I. RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Research 2000 60 2845-2849. (Pubitemid 30395804)
32. Santoro M, Melillo RM & Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. European Journal of Endocrinology 2006 155 645-653. (doi:10.1530/eje.1.02289)
33. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G & Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994 9 509-516. (Pubitemid 24041530)
34. Salvatore D, Barone MV, Salvatore G, Melillo RM, Chiappetta G, Mineo A, Fenzi G, Vecchio G, Fusco A & Santoro M. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in RET and RET-derived oncoproteins. Journal of Clinical Endocrinology and Metabolism 2000 85 3898-3907. (doi:10.1210/jc.85.10. 3898)
35. Sugg SL, Ezzat S, Rosen IB, Freeman JL & Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. Journal of Clinical Endocrinology and Metabolism 1998 83 4116-4122. (doi:10.1210/jc.83. 11.4116)
36. Xu X, Quiros RM, Gattuso P, Ain KB & Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Research 2003 63 4561-4567. (Pubitemid 36951030)
37. El-Abdallah AA & Junaid TA. Overexpression of wild-type c-RET and zero prevalence of RET/PTC rearrangements are associated with papillary thyroid cancer (PTC) in Kuwait. Experimental and Molecular Pathology 2011 90 61-65. (doi:10.1016/j.yexmp.2010.10.002)
38. Hieber L, Huber R, Bauer V, Schaffner Q, Braselmann H, Thomas G, Bogdanova T & Zitzelsberger H. Chromosomal rearrangements in post-Chernobyl papillary thyroid carcinomas: evaluation by spectral karyotyping and automated interphase FISH. Journal of Biomedicine & Biotechnology 2011 2011 693691. (doi:10.1155/2011/693691)
39. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA &Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 2000 290 138-141. (doi:10.1126/science.290.5489.138)
40. DeLellis RA & Williams D. Thyroid and parathyroid tumors. In World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Endocrine organs, pp 51-56. Eds RA DeLellis, RV Lloyd & PU Heitz, Geneva: WHO Press, 2003.
41. Cheung CC, Ezzat S, Ramyar L, Freeman JL & Asa SL. Molecular basis off hurthle cell papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2000 85 878-882. (doi:10.1210/jc.85.2.878)
42. Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, Lazzi S, Monaco M, Mazzuchelli L, Tosi P, Santoro M & Fusco A. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. Journal of Clinical Endocrinology and Metabolism 2002 87 364-369. (doi:10.1210/jc.87.1.364)
43. Cetta F, Chiappetta G, Melillo RM, Petracci M, Montalto G, Santoro M & Fusco A. The RET/PTC1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 1998 83 1003-1006. (doi:10.1210/jc.83.3.1003)
44. Papotti M, Volante M, Giuliano A, Fassina A, Fusco A, Bussolati G, Santoro M & Chiappetta G. RET/PTC activation in hyalinizing trabecular tumors of the thyroid. American Journal of Surgical Pathology 2000 24 1615-1621. (doi:10.1097/00000478-200012000-00004)
45. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H &Fagin JA. Distinct pattern of RET oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research 1997 57 1690-1694. (Pubitemid 27199660)
46. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, Tronko ND, Bogdanova TI, Chiappetta G, Viglietto G, Pentimalli F, Salvatore G, Fusco A, Santoro M &Vecchio G. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. Journal of Clinical Endocrinology and Metabolism 1999 84 4232-4238. (doi:10.1210/jc.84.11. 4232)
47. Jacob P, Kenigsberg Y, Zvonova I, Goulko G, Buglova E, Heidenreich WF, Golovneva A, Bratilova AA, Drozdovitch V, Kruk J, Pochtennaja GT, Balonov M, Demidchik EP & Paretzke HG. Childhood exposure due to the Chernobyl accident and thyroid cancer risk in contaminated areas of Belarus and Russia. British Journal of Cancer 1999 80 1461-1469. (doi:10.1038/sj.bjc.6690545)
48. Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D & Klugbauer S. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clinical Cancer Research 2000 6 1093-1103. (Pubitemid 30159372)
49. Fusco A, Chiappetta G, Hui P, Garcia-Rostan G, Golden L, Kinder BK, Dillon DA, Giuliano A, Cirafici AM, Santoro M, Rosai J & Tallini G. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. American Journal of Pathology 2002 160 2157-2167. (doi:10.1016/S0002-9440(10)61164-9)
50. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML & Fusco A. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clinical Cancer Research 1998 4 287-294. (Pubitemid 28122740)
51. Powell DJ Jr, Russell J, Nibu K, Li G, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A & Rothstein JL. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Research 1998 58 5523-5528. (Pubitemid 28551140)
52. Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, Multhaupt H, Atkins JP, Rosen MR, Keane WM &Rothstein JL. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 1997 107 95-100. (doi:10.1097/00005537-199701000- 00019)
53. Sheils OM, O'Eary JJ, Uhlmann V, Lattich K & Sweeney EC. RET/PTC-1 activation in Hashimoto thyroiditis. International Journal of Surgical Pathology 2000 8 185-189. (doi:10.1177/106689690000800305)
54. Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, Qumsiyeh MB, Rothstein JL, Fusco A, Santoro M, Zitzelsberger H & Tallini G. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 2414-2423. (doi:10.1210/jc.2006-0240)
55. Dailey ME, Lindsay S & Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. A.M.A. Archives of Surgery 1955 70 291-297.
56. Gasbarri A, Sciacchitano S, Marasco A, Papotti M, Di Napoli A, Marzullo A, Yushkov P, Ruco L & Bartolazzi A. Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis. British Journal of Cancer 2004 91 1096-1104. (Pubitemid 39336248)
57. Hunt JL, Baloch ZW, Barnes L, Swalsky PA, Trusky CL, Sesatomi E, Finkelstein S & LiVolsi VA. Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis. Endocrine Pathology 2002 13 321-330. (doi:10.1385/EP:13:4:321)
58. Prasad ML, Huang Y, Pellegata NS, De la Chapelle A & Kloos RT. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 2004 45 39-46. (doi:10.1111/j.1365-2559.2004.01876.x)
59. Cinti R, Yin L, Ilc K, Berger N, Basolo F, Cuccato S, Giannini R, Torre G, Miccoli P, Amati P, Romeo G & Corvi R. RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenetics and Cell Genetics 2000 88 56-61. (doi:10.1159/000015485)
60. Santoro M, Melillo RM, Grieco M, Berlingieri MT, Vecchio G &Fusco A. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth & Differentiation 1993 4 77-84.
61. Wang J, Knauf JA, Basu S, Puxeddu E, Kuroda H, Santoro M, Fusco A & Fagin JA. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Molecular Endocrinology 2003 17 1425-1436. (doi:10.1210/me.2003-0041)
62. Jhiang SM, Cho JY, Furminger TL, Sagartz JE, Tong Q, Capen CC &Mazzaferri EL. Thyroid carcinomas in RET/PTC transgenic mice. Recent Results in Cancer Research 1998 154 265-270.
63. Gandhi M, Medvedovic M, Stringer JR & Nikiforov YE. Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene 2006 25 2360-2366. (doi:10.1038/sj.onc.1209268)
64. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A & Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 2005 115 1068-1081. (doi:10.1172/JCI22758)
65. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A & Pierotti MA. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. PNAS 2005 102 14825-14830. (doi:10.1073/pnas.0503039102)
66. Vitale M, Di Matola T, Fenzi G, Illario M & Rossi G. Fibronectin is required to prevent thyroid cell apoptosis through an integrin-mediated adhesion mechanism. Journal of Clinical Endocrinology and Metabolism 1998 83 3673-3680. (doi:10.1210/jc.83.10.3673)
67. V600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 2011 16 296-309. (doi:10.1634/theoncologist.2010-0317)
68. Zou M, Shi Y & Farid NR. Low rate of RET proto-oncogene activation (PTC/RetTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer 1994 73 176-180. (doi:10.1002/1097-0142(19940101)73:1〈176::AID- CNCR2820730130〉3.0.CO;2-T)
69. Lam AK, Montone KT, Nolan KA & Livolsi VA. RET oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters. Human Pathology 1998 29 565-568. (doi:10.1016/S0046-8177(98)80004-X)
70. Mayr B, Potter E, Goretzki P, Ruschoff J, Dietmaier W, Hoang-Vu C, Dralle H & Brabant G. Expression of RET/PTC1, -2, -3, -delta 3 and -4 in German papillary thyroid carcinoma. British Journal of Cancer 1998 77 903-906. (doi:10.1038/bjc.1998.149)
71. Sheils OM, O'Leary JJ & Sweeney EC. Assessment of RET/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR. Journal of Pathology 2000 192 32-36. (doi:10.1002/1096-9896(2000)9999:9999〈::AID- PATH668〉3.0.CO;2-F)
72. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL &Tuttle RM. The RET/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. Journal of Clinical Endocrinology and Metabolism 2000 85 1170-1175. (doi:10.1210/jc.85.3.1170)
73. Chua EL, Wu WM, Tran KT, McCarthy SW, Lauer CS, Dubourdieu D, Packham N, O'Brien CJ, Turtle JR & Dong Q. Prevalence and distribution of RET/PTC 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. Journal of Clinical Endocrinology and Metabolism 2000 85 2733-2739. (doi:10.1210/jc.85.8. 2733)
74. Puxeddu E, Moretti S, Giannico A, Martinelli M, Marino C, Avenia N, Cristofani R, Farabi R, Reboldi G, Ribacchi R, Pontecorvi A & Santeusanio F. RET/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. European Journal of Endocrinology 2003 148 505-513. (doi:10.1530/eje.0.1480505)
75. Rhoden KJ, Johnson C, Brandao G, Howe JG, Smith BR & Tallini G. Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Laboratory Investigation; A Journal of Technical Methods and Pathology 2004 84 1557-1570. (doi:10.1038/labinvest.3700198)
76. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A &Vigneri R. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocrine-Related Cancer 2008 15 191-205. (doi:10.1677/ERC-07-0212)
77. Basolo F, Giannini R, Monaco C, Melillo RM, Carlomagno F, Pancrazi M, Salvatore G, Chiappetta G, Pacini F, Elisei R, Miccoli P, Pinchera A, Fusco A & Santoro M. Potent mitogenicity of the RET/ PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. American Journal of Pathology 2002 160 247-254. (doi:10.1016/S0002-9440(10)64368-4)
78. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW & Nikiforov YE. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. American Journal of Surgical Pathology 2006 30 216-222. (doi:10.1097/01.pas.0000176432.73455.1b)
79. Sapio MR, Posca D, Raggioli A, Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Troncone G, Caleo A, Rossi G, Fenzi G &Vitale M. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clinical Endocrinology 2007 66 678-683. (doi:10.1111/j.1365-2265.2007.02800.x)
80. Musholt TJ, Fottner C, Weber MM, Eichhorn W, Pohlenz J, Musholt PB, Springer E & Schad A. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World Journal of Surgery 2010 34 2595-2603. (doi:10.1007/s00268-010- 0729-4)